Results 81 to 90 of about 1,262,540 (308)

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. [PDF]

, 2016
BACKGROUND: Outcome of low-grade glioma (WHO grade II) is highly variable, reflecting molecular heterogeneity of the disease. We compared two different, single-modality treatment strategies of standard radiotherapy versus primary temozolomide ...
Balana, C., Baumert, B.G., Brandes, A.A., Bravo-Marques, J., Bromberg, J.E., Capper, D., Chinot, O., Clement, P.M., Dhermain, F., Dif, N., Enting, R., Feuvret, L., Gijtenbeek, J.M., Gorlia, T., Hartmann, C., Hassel, M.B., Hegi, M.E., Hoang-Xuan, K., Kantor, G., Kros, J.M., Kurscheid, S., Lacombe, D., Marosi, C., Mason, W.P., Nordal, R.A., Rees, J., Reijneveld, J.C., Reni, M., Rossiter, J.P., Ryan, G., Stupp, R., Taphoorn, M.J., Thiessen, B., Tzuk-Shina, T., van den Bent, M.J., von Deimling, A., Wick, W.   +36 more
core   +6 more sources

Chordoma. Clinical characteristics, management and prognosis of a case series of 25 patients [PDF]

, 2010
Background: Adequate surgery still remains the only curative treatment of chordoma. Interesting clinical data on advanced disease with molecularly targeted therapies were reported.Methods: We described the clinical outcome of a series of chordoma ...
Virginia Ferraresi, Carmen Nuzzo, Carmine Zoccali, Ferdinando Marandino, Antonello Vidiri, Nicola Salducca, Massimo Zeuli, Diana Giannarelli, Francesco Cognetti, Roberto Biagini, A Jemal, R Chugh, CE Peña, JM Mirra, NL Higinbotham, C Catton, PW Chambers, S Boriani, F Tzortzidis, D Baratti, D Schulz-Ertner, DC Weber, GF Fleming, E Tamborini, S Stacchiotti, H Hof, K Schönegger, ZL Gokaslan, HY Zhang, P Bergh, KL Foweraker, PA Forsyth, BJ Cummings, P Gabriele, GC Feigl, HD Suit, M Austin-Seymour, M Austin-Seymour, G Noël, R Chugh, PG Scimeca, A Azzarelli, PG Casali, PG Casali, PM Weinberger, S Stacchiotti   +45 more
core   +1 more source

Feasibility and Preliminary Efficacy of Integrative Neuromuscular Training for Childhood Cancer Survivors: A Pilot Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Survivors of childhood acute lymphoblastic leukemia (ALL) often exhibit early deficits in muscle and movement competence, which can compromise long‐term health. Integrative neuromuscular training (INT), a multifaceted approach combining fundamental movement activities with strength exercises, may help address these deficits during ...
Anna Maria Markarian, Robert U. Newton, Dennis R. Taaffe, Nicholas G. Gottardo, Santosh Valvi, Carolyn J. Peddle‐McIntyre, Jodie Cochrane Wilkie, Daniel A. Galvão   +7 more
wiley   +1 more source

Diagnostic characteristics, treatment outcomes, and prognostic factors in glucagonomas

Endocrine Oncology
Objective: Glucagonomas are rare islet cell tumours, accounting for 2% of such tumours, with an annual incidence of 0.01–0.1 per million. This study aimed to describe diagnostic characteristics and treatment outcomes in patients with glucagonoma from a ...
Eleni Armeni, Alexander Branton, Juliana Porto, Dalvinder Mandair, Aimee R Hayes, Aspasia Manta, Shaunak Navalkissoor, Gopinath Gnanasegaran, Ann-Marie Quigley, Ashley B Grossman, Martyn Caplin, Christos Toumpanakis   +11 more
doaj   +1 more source

Melphalan 140mg/m2 or 200mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party [PDF]

, 2017
Melphalan at a dose of 200mg/m2 is standard conditioning prior to autologous haematopoietic stem cell transplantation for multiple myeloma, but a dose of 140mg/m2 is often used in clinical practice in patients perceived to be at risk of excess toxicity ...
Anagnostopoulos, A, Apperley, JF, Auner, HW, Blaise, D, Browne, P, Garderet, L, Iacobelli, S, Isaksson, C, Jantunen, E, Knol-Bout, C, Kobbe, G, Krejci, M, Kröger, N, Lenhoff, S, Morris, C, Pohlreich, D, Russell, NH, Sbianchi, G, Schaap, N, Scheid, C, Schönland, SO, Tanase, A, Touzeau, C, Wiktor-Jedrzejczak, W, Yakoub-Agha, I   +24 more
core   +3 more sources

Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival [PDF]

JNCI: Journal of the National Cancer Institute, 2009
Whether progression-free survival (PFS) or overall survival (OS) is the more appropriate endpoint in clinical trials of metastatic cancer is controversial. In some disease and treatment settings, an improvement in PFS does not result in an improved OS.We partitioned OS into two parts and expressed it as the sum of PFS and survival postprogression (SPP).
Kristine R, Broglio, Donald A, Berry
openaire   +2 more sources

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands

Health and Quality of Life Outcomes, 2012
Background Gefitinib, a tyrosine kinase inhibitor, is an effective treatment in advanced non-small cell lung cancer (NSCLC) patients with an activating mutation in the epidermal growth factor receptor (EGFR).
Verduyn S, Biesma Bonne, Schramel Franz MNH, van der Scheer Feike W, Langenfeld Merel K, de Peuter Maria A, Dingemans Anne-Marie C   +6 more
doaj   +1 more source

Phosphatidylinositol 4‐kinase as a target of pathogens—friend or foe?

FEBS Letters, EarlyView.
This graphical summary illustrates the roles of phosphatidylinositol 4‐kinases (PI4Ks). PI4Ks regulate key cellular processes and can be hijacked by pathogens, such as viruses, bacteria and parasites, to support their intracellular replication. Their dual role as essential host enzymes and pathogen cofactors makes them promising drug targets.
Ana C. Mendes, Guilherme M. Azevedo, Amanda P. Barcellos, Diana Bahia   +3 more
wiley   +1 more source

The role of Lobectomy in Glioblastoma management: A Retrospective series

Brain and Spine
Introduction: Treatment choices for glioblastoma (GB) remain scarce. Multiple clinical studies have demonstrated the importance of supramaximal resection.
Christina K. Arvaniti, Alexandros G. Brotis, Jacob S. Young, Sivani Sivanrupan, Gracia Menna, Masahiro Nishide, Philippe Schucht, Mitchel Berger, Kostas N. Fountas   +8 more
doaj   +1 more source